Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
Main Authors: | Michael Migden, MD, Carmen Loquai, MD, PhD, Caroline Robert, MD, PhD, Jean-François Baurain, MD, PhD, Nicholas Squittieri, MD, Ramon Arntz, Dr, Jörg Dierlamm, BSc, Brigitte Dréno, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | JAAD International |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328722001365 |
Similar Items
-
Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy
by: Carlos González-Cruz, MD, et al.
Published: (2024-04-01) -
Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution
by: Hailey Grubbs, DO, et al.
Published: (2023-08-01) -
A Case of Super-giant Basal Cell Carcinoma Initially Diagnosed as Multiple Traumas
by: Junko Okano, MD, PhD, et al.
Published: (2023-02-01) -
Educational Case: Basal Cell Carcinoma
by: Katie A. O’Connell MS, et al.
Published: (2021-03-01) -
Treatment and Outcomes for Cutaneous Periauricular Basal Cell Carcinoma: A 16-Year Institutional Experience
by: Mallory Peters, et al.
Published: (2020-10-01)